Cyprotex, wholly owned by Evotec , is a leading company specializing in predictive toxicology and ADME-Tox – Toxicology services. The Company was established in 1999 and works with more than 1,500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including cell-based assays, in silico models and databases to predict how a new drug will be processed in the human body and what effects it might have on the body.

We strive to exceed our customers' expectations in the provision of our services and maintain our position as the leading ADME-Tox outsourced service provider to the pharmaceutical and chemical industries. We focus on our core deliverables of high-quality data at the most cost-effective price to our customers while expanding our customer base and deepen the relationships with our existing clients. We invest in R&D to introduce and further develop unique, cutting-edge solutions and services. We believe in sharing our knowledge and expertise within the industry and focus on enhancing global recognition of the Cyprotex brand.